LSP1-2111

LSP1-2111 is a **selective orthosteric agonist of the metabotropic glutamate receptor 4 (mGlu4)**, part of the group III mGlu receptors in the central nervous system[1][2][4]. It acts by preferentially stimulating mGlu4, particularly at lower doses, displaying **approximately 30-fold selectivity** for mGlu4 over other group III mGlu receptors[1]. In preclinical studies, LSP1-2111 shows antipsychotic-like, anxiolytic, and anti-parkinsonian activities in rodents and marmosets, attributed to the modulation of glutamatergic neurotransmission and potential reduction of abnormal glutamate release[1][2][3][4]. Efficacy has been demonstrated in animal models for **Parkinson's disease, anxiety, and psychosis**, with effects mediated partly by serotonergic and GABAergic systems[2][3][4]. Importantly, LSP1-2111 is brain-penetrant and has no appreciable off-target interactions at concentrations up to 10 μM[1][4].